TELESTA THERAPEUTICS INC T.TST

one missing item on website

[beechguy]

I wish somewhere they would put that they had a CRR of over 35% on Pappilary. Carcinoma InSitu was 20%, but that is only 10% of the population base, whereas 90% are Pappilary. That means over a third of the most prevalent patients will be cured. When factoring in adding MCNA as an adjuvant at immediate post Turbt setting that number jumps up almost to around 50%. SUMMARY? MCNA is not only the most efficacious by country mile (less than 10% effective for Valstar and highly toxic) and MCNA is well tolerated with less than 1.5% of patient experiencing mild to moderate side effects. Don't think for a second partners or acquirers are not well aware MCNA. It's only a matter of time with multiple term sheets in play that something very big big is going to happen. Next halt will be a bIggy. Hope you are loaded up ...i know i am. GLTA beech

[DryBones]

You mean they stiill cant get it together on the webpage?   PS Be carefully of the beechifier.  While TST is a very good bet, it is still a bet.  A bet that can be beset by delays, major delays.   Only buy on the cheap, and take a little profit to cover some of your costs on a price rise.  That is my advise for those who have a lot invested here  There will be some

[DamnYankees]

beach guy where do you get the 35 and 50% figures from? Neither of these DF rates are evident in the Urology Journal trial review that is on the website ( the one that apparently no one has read). Are these advanced findings that maybe they are only presenting to partners because they are outside of the scope of the Phase 3 trial? Another question I have that maybe you might answer. Who is this

[beechguy]

the trial was with both papillary and carsinoma in situ. Carcinoma in situ (the harder to treat poplulation) was 20% CRR, the more prevalent Papillary (90% of refractory bladder cancers) had a CRR of 35%. Endo pharmas Valstar has a CRR of less than 10% approved for carcinoma in situ patients. It is the only approved refractory treatment for carcinoma in situ bladder cancer patients who fail BCG

[RetailRube]

I agree with the efficacy data Beech is quoting.  However, I am am reluctant to fault TST management for not promoting it aggressively.  It may be a smart strategy on their part. The reason has to do with statistics and how you do statistical tests on small sample sizes.  TST is making their BLA submission to the FDA using the 129 people in the Phase 3a trial results.  This

[beechguy]

Great post Rube. Potential partners would run those numbers 6 ways from Sunday and would understand that. I guess I was more hoping the investment public would starts to grasp what the numbers meant, and how efficacious MCNA is against the (vast majority) refractory Papillary group. Keep up the good work! Beech

[cheetio]

. Who is this shareholder presentation intended for? Maybe trying to suck these guys in again..........Updated April 22, 2013 at 16h19 The Solidarity Fund QFL has lost nearly $ 7 million in Bioniche Life Science, an Ontario biopharmaceutical research company. The institution has liquidated its stake in Bioniche last Friday during the trading session. The transaction of about $ 1.6 million to the